Source: Virtual Congress 2020 – Comorbidities/multimorbidites and mortality in patients with chronic lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Saeed (Hellerup, Denmark), J. Eklöf (Hellerup, Denmark), I. Achir (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark), H. Meteran (Hellerup, Denmark), A. Løkke (Vejle, Denmark), T. Sørensen (Hellerup, Denmark), F. Knop (Hellerup, Denmark), J. Jensen (Hellerup, Denmark). Long-term use of inhaled corticosteroids and the risk of type 2 diabetes in COPD. 1434

Member's Comments

No comment yet.

Related content which might interest you: Risks of diabetes mellitus and hyperglycaemic adverse events in patients with COPD taking inhaled corticosteroids Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Risks of diabetes mellitus and hyperglycaemic adverse events in patients with asthma taking inhaled corticosteroids Source: Annual Congress 2011 - Asthma management and response Year: 2011 Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 Year: 2017 Safety profile of COPD medications in COPD patients with concomitant diabetes mellitus Source: International Congress 2017 – COPD management Year: 2017 Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes Source: International Congress 2014 – Markers Year: 2014 Combination therapy of inhaled corticosteroids and long-acting beta2-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking Source: Eur Respir J 2006; 28: Suppl. 50, 454s Year: 2006 Impact of inhaled corticosteroids in patients with cardiovascular disease Source: Eur Respir Monogr 2020; 88: 251-263 Year: 2020 Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002 Long-term inhaled corticosteroid use in COPD and the risk of fracture in men and women Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Long-term adherence to inhaled corticosteroids and asthma control in adult-onset asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Long-term use of inhaled glucocorticoids in stable chronic obstructive pulmonary disease patients and risk of diabetes mellitus: systematic review of the literature Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017 Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016